Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04546113
Other study ID # ANEST-03-2019
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 7, 2021
Est. completion date February 4, 2023

Study information

Verified date March 2022
Source Institut Mutualiste Montsouris
Contact Fehmi KATTOU, MD
Phone 0156616263
Email fehmi.kattou@imm.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this randomized double-blind study is to compare the analgesic efficacy of the bilateral Erector Spinae Plane (ESP) block versus the bilateral Thoracic Paravertebral block (TPVB), by ultrasound-guided single injection in patients who underwent sternotomy for cardiac surgery.


Description:

Cardiac surgery causes moderate to severe postoperative pain during the first 24 - 48 post-operative hours. This pain is greatly increased by mobilization (respiratory physiotherapy) and leads to the consumption of morphine. Appropriate analgesia, along with a reduction in morphine consumption are important factors in reducing morbidity after cardiac surgery and allow better postoperative rehabilitation. Recently, the concept of multimodal analgesia has become established, which corresponds to ensuring optimal analgesia through the use of non-morphine drugs associated with locoregional analgesia. During cardiac surgery, Paravertebral block (TPVB) technique is the first line of reference in our establishment. Lately, a new approach of blocking the intercostal nerves called Erector Spinae Plane block (ESP) has been discovered. It is a technique that seems simpler and safer than TPVB. Until now, the analgesic efficacy of the ESP block compared to TPVB after cardiac surgery by sternotomy has never been studied.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date February 4, 2023
Est. primary completion date February 4, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Undergoing any (scheduled) surgery of the heart (valve or coronary surgery) via a median sternotomy - Physical status classification (ASA) =3 - Patients benefiting from a Social Security scheme or benefiting from it through a third party Exclusion Criteria: - Emergency cardiac surgery - Exclusion criteria related to cardiac surgery with thoracotomy, occurrence of aortic dissection, redo surgery. - Aortic counterpulsation - Preoperative cardiogenic shock - LVEF< 30% - Severe preoperative chronic or acute renal failure with creatinine clearance less than 30 mL / min according to the MDRD formula - Pre-existing psychiatric pathology, including addiction to opioids - Physical or intellectual incapacity to use a PCA - Known allergy or hypersensitivity to any of the study drugs or analgesia protocol (ropivacaine, paracetamol, opioids) - Contraindication for performing the paravertebral block and Erector of the spine (ESP): Infection at the site of injection, severe hemostasis disorder, thoracic spinal pathology making the procedure difficult or dangerous to operate - Obese patient (BMI> 30kg / m2) with poorly perceived thoracic spinous processes. - vulnerable patients(Pregnant or breastfeeding women, persons benefiting from enhanced protection, namely persons deprived of their liberty by a judicial or administrative decision, adults under legal protection).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Ultrasound-guided Bilateral Paravertebral Block performed with a 20 ml injection of ropivacapine 3,75 mg/ml/side
Bilateral injection of 20 ml of Ropivacaïne 3,75 mg/ml/side
Ultrasound-guided Bilateral Erector Spinae plane Block performed with a 20 ml injection ropivacaine 3,75 mg/ml/side
Bilateral injection of 20 ml of Ropivacaïne 3,75 mg/ml/side

Locations

Country Name City State
France Institut Mutualiste montsouris Paris

Sponsors (2)

Lead Sponsor Collaborator
Institut Mutualiste Montsouris Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain assessment Pain assessment measured with Visual Analogue Scale (VAS) between 0 (no pain, best outcome) and 10 (worst possible pain, worst outcome) at mobility, (respiratory effort during peak flow meter measurment) 6 hours from the end of the surgery
Secondary Efficacy of the block (a) Based on hemodynamic response to incision and sternotomy (increase in heart rate, measured in beats per minute (bpm) During the surgery
Secondary Efficacy of the block (b) Based on variations in the ANI (Anti Nociceptive Index) value (scale from 0 (maximum of nociception) to 100 (complete analgesia)) During the surgery
Secondary Efficacy of the block (c) Based on hemodynamic response to incision and sternotomy (increase in blood pressure, measured in mmHg). Blood pressure numbers of less than 120/80 mm Hg are considered within the normal range. During the surgery
Secondary Intraoperative sufentanil consumption Intraoperative sufentanil consumption (at the discretion of physicians based on haemodynamic variations and ANI values). Measured in ng/ml. During the surgery
Secondary Postoperative pain assessment Pain assessment measured with Visual Analogue Scale between 0 (no pain, best outcome) and 10 (worst possible pain and and worst outcome) at mobility, (respiratory effort during peak flow meter measurment) 3, 6, 12, 24, 48 hours from the end of the surgery
Secondary Postoperative Morphine consumption Morphine PCA consumption, measured in mg/h. 3, 6, 12, 24, 48 hours from the end of the surgery
Secondary Side effects associated to morphine Incidence of post operative nausea, vomiting and sedation 3, 6, 12, 24, 48 hours from the end of the surgery
Secondary Spirometry parameters. Spirometry measures two key factors: expiratory forced vital capacity (FVC) and forced expiratory volume in one second (FEV1). We will look at these as a combined number known as the FEV1/FVC ratio.The higher the percentage derived from your FEV1/FVC ratio, in the absence of restrictive lung disease that causes a normal or elevated FEV1/FVC ratio, the healthier your lungs are. A low ratio suggests that something is blocking your airways 24 hours from the end of the surgery
Secondary Complication(s) associated to the procedure Pneumothorax, major hematoma, sympathetic block 48 hours from the end of the surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05534230 - Dexmedetomidine for Pain Reduction in CABG N/A
Recruiting NCT06275698 - HONEY for the Treatment of POst-Tonsillectomy Pain N/A
Recruiting NCT04436224 - Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation Phase 4
Not yet recruiting NCT04548323 - Hypoalgesic Effects of Walking and Running Imagined
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT04394481 - Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery Phase 4
Completed NCT04690647 - The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement. N/A
Completed NCT05034601 - ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure N/A
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05454202 - Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
Recruiting NCT04554186 - Serratus Anterior Plane Block Versus Thoracic Paravertebral Block. N/A
Suspended NCT04860635 - Safety of F14 Following Total Knee Replacement Phase 2/Phase 3
Not yet recruiting NCT04519463 - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing Early Phase 1
Completed NCT02916342 - Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks Phase 4
Completed NCT03206554 - Local Infiltration Analgesia in Total Knee Arthroplasty Phase 2
Not yet recruiting NCT02549118 - Tenoxicam for Intrapartum Analgesia Phase 2
Not yet recruiting NCT02190760 - Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block. N/A
Completed NCT01789606 - Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet Phase 3
Completed NCT01299584 - ULTIVA Post Marketing Surveillance N/A
Completed NCT00137085 - Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation N/A